N-Acetyl Semax

Cognitive & Nootropic

aka N-Acetyl Semax amidate · Acetylated Semax · Ac-Semax

Compare

Formula

MW (Da)

Half-life

~hours (acetylated; longer than Semax)

Saves

Overview

In research catalogs, this compound is usually called N-Acetyl Semax amidate — a modified version of Semax (an ACTH(4-10)-derived heptapeptide). PubChem identifies the modified molecule, but indexed clinical evidence for the modified form is limited. Most meaningful biological and clinical discussion still comes from the parent peptide Semax.

Mechanism

Parent-Semax studies support a neurotrophic and neuroprotective profile, especially through effects on BDNF/trkB-related signaling and gene-expression changes after ischemic injury. In humans, Semax has been studied intranasally in healthy volunteers, where it altered default-mode-network activity, and in Russian stroke literature, where courses such as 6,000 mcg/day for 10 days or acute-stroke regimens of 12 mg/day or 18 mg/day were associated with improved functional-recovery markers. These findings explain why N-Acetyl Semax is marketed as a nootropic variant — but they do not establish equivalent efficacy for the acetylated form.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Parent-Semax neurotrophic and stroke-recovery signals

Parent-Semax research supports BDNF/trkB-related signaling and gene-expression changes after ischemic injury. Russian stroke literature reports improved functional-recovery markers at 6,000 mcg/day for 10 days, or acute-stroke regimens of 12–18 mg/day.

[nsemax-pubmed-semax]

clinical

Default-mode-network changes in healthy volunteers (parent peptide)

Intranasal Semax altered default-mode-network activity in healthy volunteers — a functional-brain signal consistent with the nootropic framing.

[nsemax-pubmed-semax]

clinical

Reported side effects

Limited extensive trial evidence for the acetylated form
anecdotal
Extensive clinical-trial evidence for N-Acetyl Semax specifically was not retrieved; the safety literature for parent Semax in indexed English sources is also not robust by modern Western standards.
FDA: limited safety information; aggregation/impurity concerns for compounded Semax
clinical
FDA now states that compounded semax products have limited safety-related information and may present peptide-aggregation and impurity concerns. This caution applies conceptually to the acetylated analog as well.

Dosing notes

There is no standardized human dosing for N-Acetyl Semax. Parent-Semax regimens reported in the literature are intranasal and indication-specific: 6,000 mcg/day for 10 days, or acute-stroke 12 mg/day or 18 mg/day.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

No approved label exists with product-specific N-Acetyl Semax storage instructions. Default synthetic-peptide handling: frozen, dry, light-protected lyophilized storage; careful aliquoting after reconstitution.

Vendors carrying N-Acetyl Semax

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about N-Acetyl Semax.

No questions yet. Be the first to ask.

References

[nsemax-pubchem]
N-Acetyl Semax amidate (PubChem CID 172638603)
PubChem · PubChem
Source
[nsemax-pubmed-semax]
Semax neurotrophic and stroke-recovery research
Authors per PubMed entry · PubMed
Source
[nsemax-peptidesorg]
N-Acetyl Semax amidate research profile (peptides.org)
peptides.org · peptides.org
Source